[Use of ultrahigh frequency electromagnetic irradiation in the treatment of infectious complications in patients with hemoblastoses]. / Primenenie élektromagnitnykh izluchenii sverkhvysokoi chastoty dlia lecheniia infektsionnykh oslozhnenii u bol'nykh gemoblastozami.

Electromagnetic radiation microwave frequency (MVF) was used in the complex treatment of local infectious infiltrates, as well as chronic bronchitis and acute pneumonia. Preliminary in vitro studies have shown that MVF does not produce any unfavourable effect on the immune system and does not induce the main disease progressing. Indications and contraindications have been described for MVF use in the treatment of patients with hemoblastosis. The method of MVF application includes a gradual increase of intensity and time of MVF action on the affected focus. The course of treatment consists of 8-12 sessions, the improvement being recorded after 3-5 sessions. It has been found that MVF induces improvement of red blood cell rheologic properties, arrest of local inflammatory processes, during shorter terms as compared to patients who were not treated by MVF, as well as it produces a favourable effect on hemodynamic parameters. Complete arresting of the inflammatory process has been recorded in 94.0% of patients with hemoblastosis. The results of the investigation permit recommending MVF in the treatment of infectious (postinjection and postbemorrhagic) infiltrates, chronic bronchitis and acute pneumonia that complicate the course of hemoblastosis. This method of treatment not only diminishes the terms of infectious process elimination, but also increases the effectiveness of their control.

[Radiotherapy of epidemic Kaposi's sarcoma in patients with AIDS. Analysis of 149 cases treated by extended and/or localized cutaneous irradiation]. / Radiothérapie du sarcome de Kaposi épidémique chez les patients porteurs de SIDA. Analyse de 149 cas traités par irradiation cutanée étendue et/ou localisée.

Between June 1986 and December 1988, 149 patients with AIDS-related Kaposi's sarcoma were treated by cutaneous irradiation in our department. According to Mitsuyasu's staging, 34 patients (23 p. 100) were stage I, 82 (55 p. 100) stage II and 33 (22 p. 100) stage IV; no stage III was reported. Fifty eight patients (39 p. 100) had previously presented with one or several opportunistic infections. Ninety four patients (63 p. 100) had previously received treatment with interferon in 85 (57 p. 100) and/or Velbe in 43 (29 p. 100). 319 cutaneous localisations were treated, 59 p. 100 by extended cutaneous irradiation, using 4 and/or 8 MeV electron beam energy, and 41 p. 100 by localized irradiation, using 45 kVX-ray energy, 2.5 Gy/fraction, 4 times a week by split course 20 Gy then 10 Gy two weeks later. Twenty patients (13 p. 100) with oedema of the lower limbs were treated, using 4 MV photon therapy with bolus, and 3 (2 p. 100) were treated for lesions in the ENT regions. Only 131 patients were evaluable (257 localisations); 62 p. 100 obtained complete remission and 31 p. 100 partial remission after a mean period of 1.5 months (0.5-3 months). The overall tolerance was acceptable. The complications were epidermitis with some necrosis (8 p. 100), exudative epidermitis (26 p. 100), moderate epidermitis (63 p. 100) and slight reactions in 4 p. 100. The mean recurrence time was 5 1/2 months.